Precision oncology therapies that target genomic drivers of cancer are advancing at a rapid pace, yet the use of highly accurate molecular diagnostic solutions remains limited in community and regional settings where approximately 85 percent of cancer patients receive care.
ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.
For local adoption of advanced genomic analysis for cancer samples, products need to have
Accuracy – Accurately detect complex mutations
Currently available tests are designed with inherent biases that fundamentally limit their ability to detect both known and unknown alterations. They believe their purpose built Anchored Multiplex PCR (AMP™) chemistry addresses these shortcomings.
Turnaround time – Reduce time to results
Results from centralized genomic tests can take well over 20 days to be returned, depending on complexity and sample type. The products enable local testing with potential times to run the test as short as 3 to 5 days, accelerating time to results while also allowing the original clinical researcher to maintain sample custody.
Utility – Utilizes DNA, RNA and ctDNA
Investigational products to enable testing across a multitude of input types with flexibility to analyze DNA, RNA and ctDNA from blood or tissue in order to provide higher resolution and a more comprehensive view of variations.
Economics – Enable tests at local care settings
ArcherDX is developing genomic diagnostic options designed to enable use in community and regional settings where there is a lack of infrastructure and expertise to implement sophisticated genomic analysis.